Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Hazardous Products Regulations

Version of section 8.1.7 from 2022-12-15 to 2024-11-26:


Marginal note:Conversion from range to point estimate

  •  (1) If a formula in section 8.1.5 or 8.1.6 is used, an acute toxicity point estimate must be determined, in accordance with the table to subsection (2), for each ingredient for which only that ingredient’s classification category or experimentally obtained acute toxicity range is available.

  • Marginal note:More than one range

    (2) If the experimentally obtained acute toxicity range for an ingredient does not fall entirely within any of the ranges set out in column 2 of the following table, the converted acute toxicity point estimate for that ingredient for the purposes of column 3 is the lowest value of the experimentally obtained acute toxicity range.

    TABLE

    Column 1Column 2Column 3
    ItemExposure RoutesClassification Category and Associated Experimentally Obtained Acute Toxicity Range Minimum and Maximum ValuesConverted Acute Toxicity Point Estimate
    1Oral (mg/kg body weight)
    • 0 < Category 1 ≤ 5
    • 5 < Category 2 ≤ 50
    • 50 < Category 3 ≤ 300
    • 300 < Category 4 ≤ 2000
    • 0.5
    • 5
    • 100
    • 500
    2Dermal (mg/kg body weight)
    • 0 < Category 1 ≤ 50
    • 50 < Category 2 ≤ 200
    • 200 < Category 3 ≤ 1000
    • 1000 < Category 4 ≤ 2000
    • 5
    • 50
    • 300
    • 1100
    3Inhalation (gases) (ppmV)
    • 0 < Category 1 ≤ 100
    • 100 < Category 2 ≤ 500
    • 500 < Category 3 ≤ 2500
    • 2500 < Category 4 ≤ 20 000
    • 10
    • 100
    • 700
    • 4500
    4Inhalation (vapours) (mg/l)
    • 0 < Category 1 ≤ 0.5
    • 0.5 < Category 2 ≤ 2.0
    • 2.0 < Category 3 ≤ 10.0
    • 10.0 < Category 4 ≤ 20.0
    • 0.05
    • 0.5
    • 3
    • 11
    5Inhalation (dust/mist) (mg/l)
    • 0 < Category 1 ≤ 0.05
    • 0.05 < Category 2 ≤ 0.5
    • 0.5 < Category 3 ≤ 1.0
    • 1.0 < Category 4 ≤ 5.0
    • 0.005
    • 0.05
    • 0.5
    • 1.5
  • SOR/2022-272, s. 40

Date modified: